Suboxone is manufactured by Indivior. It was previously manufactured by Reckitt Benckiser Pharmaceuticals, Inc. Reckitt Benckiser Pharmaceuticals rebranded under the name Indivior in 2014. As a result, all manufacturing of Suboxone occurs under the name Indivior now.
Suboxone was originally created by Reckitt Benckiser Pharmaceuticals, Inc. The company is today known as Indivior.
The first formulation of buprenorphine for addiction treatment was known as Subutex. It only contained buprenorphine rather than Suboxone’s current formulation of buprenorphine and naloxone.
Subutex was first released in France in 1995.
Since Subutex was pure buprenorphine, it was prone to diversion as people attempted to misuse the medication by injecting it to get high. As a result, Reckitt created a combination medication, adding naloxone to buprenorphine as an abuse-deterrent component.
If a user attempts to inject Suboxone with the goal of getting high, the naloxone will be activated, blocking the effects of the buprenorphine and preventing the patient from getting high or from overdosing.
Both Subutex and Suboxone received FDA approval in the United States in 2002.
Today, Suboxone is considered the gold standard in Medication for Addiction Treatment (MAT). Suboxone works by controlling opioid withdrawal symptoms and cravings, so patients can focus on other aspects of their recovery treatment, such as therapy.
Patients remain on Suboxone on a long-term basis, for months or years. Some patients remain on Suboxone indefinitely as it continues to support their recovery.